Comparing Schrodinger (NASDAQ:SDGR) & Hims & Hers Health (NYSE:HIMS)

Schrodinger (NASDAQ:SDGR) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 21.0% of Schrodinger shares are held by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Schrodinger has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.

Profitability

This table compares Schrodinger and Hims & Hers Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrodinger	-68.49%	-48.24%	-24.21%
Hims & Hers Health	6.05%	24.67%	9.37%

Earnings & Valuation

This table compares Schrodinger and Hims & Hers Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$207.54 million	5.96	-$187.12 million	($2.41)	-6.97
Hims & Hers Health	$1.48 billion	4.84	$126.04 million	$0.54	58.11

Hims & Hers Health has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Schrodinger and Hims & Hers Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1	4	6	0	2.45
Hims & Hers Health	3	11	3	1	2.11

Schrodinger currently has a consensus target price of $24.33, suggesting a potential upside of 44.93%. Hims & Hers Health has a consensus target price of $44.54, suggesting a potential upside of 41.93%. Given Schrodinger’s stronger consensus rating and higher probable upside, research analysts clearly believe Schrodinger is more favorable than Hims & Hers Health.

Summary

Hims & Hers Health beats Schrodinger on 9 of the 15 factors compared between the two stocks.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.